Effects of Metformin in a Non-Diabetic Patient Population
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
Metformin has a well-established safety profile and it has become clear that metformin has
additional salutary effects, including anti-inflammatory, anti-aging, and anti-thrombotic
properties. In this study, subjects will provide both venous blood samples and stool samples
in addition to completing cognitive and physiologic testing at baseline, throughout a 90 day
exposure to metformin, and 30 days following exposure to metformin in order to evaluate their
immune, microbiome, cellular respiration, thrombotic, and inflammatory responses.